The DOI matches its Crossref record.
Activin induces cell death in hepatocytes in vivo and in vitro
Abstract
While studying endocrine responses to activin in female rats, we discovered that activin caused a marked reduction in liver mass. The regressed livers exhibited no gross signs of necrosis or infarction, but histopathological evaluation revealed extensive cell death in the centrilobular regions. The dying cells appeared to fragment into structures resembling apoptotic bodies. Liver mass and histological appearance were restored after cessation of activin infusion, indicating that on an organ level, this effect was reversible. To determine whether the effects observed in vivo were caused by direct actions on the liver, we then tested activin on isolated hepatocytes in serum-free medium. Under these conditions, activin caused many hepatocytes to undergo fragmentation, which was accompanied by a loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-reducing activity, an index of viability. We compared the effects of activin with those of transforming growth factor-β because activin is structurally related to transforming growth factor-β and because transforming growth factor-β has been shown previously to induce cell death in hepatocytes. Both proteins caused cell death of comparable magnitude, as defined by the extent of loss of MTT-reducing activity, but transforming growth factor-β was active at one tenth of the effective activin concentrations. A neutralizing monoclonal antibody to transforming growth factor-β blocked the response to transforming growth factor-β but had no effect on the response to activin. Conversely, follistatin, an activinbinding protein, blocked the response to activin but not to transforming growth factor-β. Inhibin, which antagonizes the effects of activin in many systems, had little effect on the response to activin. Activin and transforming growth factor-β differed in their onset of action; exposure to transforming growth factor-β for only 1 hr induced a maximal response, whereas maximal response to activin required its continuous presence for 24 hr. These results show a novel effect of activin on cell death in hepatocytes in vivo and in vitro, suggesting that activin may have a previously unrecognized role in regulating hepatic function. (Hepatology 1993;18:347-356).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kraupp, B. G., Ruttkay-Nedecky, B., Koudelka, H., Bukowska, K., Bursch, W., & Schulte-Hermann, R. (1995) · Hepatology · doi:10.1002/hep.1840210534 · Cited by 1,156
The Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
Ovarian Follicle Atresia: A Hormonally Controlled Apoptotic Process*
HSUEH, A. J. W., BILLIG, H., & TSAFRIRI, A. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-6-707 · Cited by 787
Roles of TGF-beta in hepatic fibrosis
Gressner, A. M. (2002) · Frontiers in Bioscience · doi:10.2741/a812 · Cited by 783
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
“In addition to being anti-mitogenic, TGF-β (and activin) has been found to induce hepatocyte apoptosis (Schwall et al. 1993; Yasuda et al. 1993; Oberhammer et al. 1991).”
BackgroundBissell, D. M., Wang, S. S., Jarnagin, W. R., & Roll, F. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118055 · Cited by 419
Roles of TGF-beta in hepatic fibrosis
Gressner, A. (2002) · Frontiers in Bioscience · doi:10.2741/gressner · Cited by 405
Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice.
Matzuk, M. M., Finegold, M. J., Mather, J. P., Krummen, L., Lu, H., & Bradley, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8817 · Cited by 374
Transforming growth factor β and the liver
Bissell, M. D., Roulot, D., & George, J. (2001) · Hepatology · doi:10.1053/jhep.2001.28457 · Cited by 348
Activins and Inhibins: Roles in Development, Physiology, and Disease
Namwanje, M., & Brown, C. W. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021881 · Cited by 294
“Strict control is necessary because dysregulated signaling has adverse effects in vivo and at the cellular level (Matzuk et al. 1992; Schwall et al. 1993; Tanimoto et al. 1999; Chen et al. 2000).”
Follistatin: A Multifunctional Regulatory Protein
Phillips, D. J., & de Kretser, D. M. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0169 · Cited by 275
Apoptosis and hepatobiliary disease
Patel, T., & Gores, G. J. (1995) · Hepatology · doi:10.1002/hep.1840210635 · Cited by 264
Roles of activin in tissue repair, fibrosis, and inflammatory disease
WERNER, S., & ALZHEIMER, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.01.001 · Cited by 209
Bartholin, L., Maguer-Satta, V., Hayette, S., Martel, S., Gadoux, M., Corbo, L., Magaud, J.-P., & Rimokh, R. (2002) · Oncogene · doi:10.1038/sj.onc.1205294 · Cited by 82
A complex role of activin A in non-alcoholic fatty liver disease
Yndestad, A., Haukeland, J. W., Dahl, T. B., Bjøro, K., Gladhaug, I. P., Berge, C., Damås, J. K., Haaland, T., Løberg, E. M., Linnestad, P., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.318 · Cited by 75
“Previously, activin A had been reported to inhibit hepatocyte growth by downregulating hepatocyte replication and inducing apoptosis (”
BackgroundcDNA cloning and expression of human activin βE subunit
Hashimoto, O., Tsuchida, K., Ushiro, Y., Hosoi, Y., Hoshi, N., Sugino, H., & Hasegawa, Y. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00157-0 · Cited by 54
Clinical and therapeutic implications of follistatin in solid tumours
SHI, L., RESAUL, J., OWEN, S., YE, L., & JIANG, W. G. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20005 · Cited by 47
de Kretser, D. M., Bensley, J. G., Pettilä, V., Linko, R., Hedger, M. P., Hayward, S., Allan, C. A., McLachlan, R. I., Ludlow, H., & Phillips, D. J. (2013) · Critical Care · doi:10.1186/cc13093 · Cited by 39
Metadata
- Authors
- Schwall, R. H., Robbins, K., Jardieu, P., Chang, L., La, C., & Terrel, T. G.
- Venue
- Hepatology
- Published
- 1993-08
- Volume
- 18
- Issue
- 2
- Pages
- 347-356
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1980346062
- Cited by
- 210
- References
- 0
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.